Literature DB >> 15505749

A prospective study of alcoholism and the risk of Parkinson's disease.

Miguel A Hernán1, Giancarlo Logroscino, Luis A García Rodríguez.   

Abstract

The lower incidence of Parkinson's disease (PD) among smokers may be explained by a protective effect of cigarette smoke, or by a tendency to avoid addictive behaviors among future PD cases. We conducted an indirect test of the latter hypothesis by comparing the incidence of PD between alcoholics and nonalcoholics in the General Practice Research Database of the United Kingdom. Our case-control study included 1,019 cases and 10,123 matched controls. Overall, we did not find a lower incidence of PD among alcoholics compared with nonalcoholics (odds ratio: 1.09; 95 % CI: 0.67, 1.78).

Entities:  

Mesh:

Year:  2004        PMID: 15505749     DOI: 10.1007/s00415-004-1705-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease.

Authors:  Miguel A Hernán; Bahi Takkouche; Francisco Caamaño-Isorna; Juan J Gestal-Otero
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

2.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

3.  MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra.

Authors:  A Zuddas; G U Corsini; S Schinelli; J N Johannessen; U di Porzio; I J Kopin
Journal:  Brain Res       Date:  1989-10-30       Impact factor: 3.252

4.  Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.

Authors:  R E Ryan; S A Ross; J Drago; R E Loiacono
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Caffeine, postmenopausal estrogen, and risk of Parkinson's disease.

Authors:  A Ascherio; H Chen; M A Schwarzschild; S M Zhang; G A Colditz; F E Speizer
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

6.  Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Authors:  J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

Review 7.  Is there a premorbid personality typical for Parkinson's disease?

Authors:  G W Paulson; N Dadmehr
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

8.  Cigarette smoking and the incidence of Parkinson's disease in two prospective studies.

Authors:  M A Hernán; S M Zhang; A M Rueda-deCastro; G A Colditz; F E Speizer; A Ascherio
Journal:  Ann Neurol       Date:  2001-12       Impact factor: 10.422

9.  Alcohol consumption and the incidence of Parkinson's disease.

Authors:  Miguel A Hernán; Honglei Chen; Michael A Schwarzschild; Alberto Ascherio
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

10.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by ethanol or acetaldehyde.

Authors:  G U Corsini; A Zuddas; U Bonuccelli; S Schinelli; I J Kopin
Journal:  Life Sci       Date:  1987-03-02       Impact factor: 5.037

View more
  22 in total

1.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Risk of fracture in patients with Parkinson's disease.

Authors:  S Pouwels; M T Bazelier; A de Boer; W E J Weber; C Neef; C Cooper; F de Vries
Journal:  Osteoporos Int       Date:  2013-02-22       Impact factor: 4.507

3.  Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.

Authors:  Marina Simeonova; Frank de Vries; Sander Pouwels; Johanna H M Driessen; Hubert G M Leufkens; Suzanne M Cadarette; Andrea M Burden
Journal:  Br J Clin Pharmacol       Date:  2018-08-09       Impact factor: 4.335

4.  Use of antidepressants and the risk of Parkinson's disease: a prospective study.

Authors:  A Alonso; L A García Rodríguez; G Logroscino; M A Hernán
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06       Impact factor: 10.154

5.  Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study.

Authors:  Laura Brighina; Nicole K Schneider; Timothy G Lesnick; Mariza de Andrade; Julie M Cunningham; David Mrazek; Walter A Rocca; Demetrius M Maraganore
Journal:  Parkinsonism Relat Disord       Date:  2009-02-04       Impact factor: 4.891

6.  Acetaldehyde and parkinsonism: role of CYP450 2E1.

Authors:  Francesca Vaglini; Cristina Viaggi; Valentina Piro; Carla Pardini; Claudio Gerace; Marco Scarselli; Giovanni Umberto Corsini
Journal:  Front Behav Neurosci       Date:  2013-06-21       Impact factor: 3.558

7.  Estrogen-related and other disease diagnoses preceding Parkinson's disease.

Authors:  Jeanne C Latourelle; Merete Dybdahl; Anita L Destefano; Richard H Myers; Timothy L Lash
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

8.  Diabetes in patients with idiopathic Parkinson's disease.

Authors:  Claudia Becker; Gunnar P Brobert; Saga Johansson; Susan S Jick; Christoph R Meier
Journal:  Diabetes Care       Date:  2008-06-16       Impact factor: 19.112

9.  Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort Study.

Authors:  Ruth Brauer; Krishnan Bhaskaran; Nishi Chaturvedi; David T Dexter; Liam Smeeth; Ian Douglas
Journal:  PLoS Med       Date:  2015-07-21       Impact factor: 11.069

Review 10.  Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.

Authors:  Kenneth Blum; Amanda Lih Chuan Chen; Thomas J H Chen; Eric R Braverman; Jeffrey Reinking; Seth H Blum; Kimberly Cassel; Bernard W Downs; Roger L Waite; Lonna Williams; Thomas J Prihoda; Mallory M Kerner; Tomas Palomo; David E Comings; Howard Tung; Patrick Rhoades; Marlene Oscar-Berman
Journal:  Theor Biol Med Model       Date:  2008-11-12       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.